trending Market Intelligence /marketintelligence/en/news-insights/trending/fKdfcSeHcv7jGXiIBJkBDg2 content esgSubNav
In This List

MediciNova's ALS treatment orphan-drug designated in Europe

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


MediciNova's ALS treatment orphan-drug designated in Europe

The European Commission designated as an orphan drug MediciNova Inc.'s MN-166 treatment for amyotrophic lateral sclerosis, or ALS.

The development offers potential benefits including protocol assistance, fee reductions and a 10-year market exclusivity once the medicine is introduced in the European market.

The drug is also designated as an orphan drug for ALS in the U.S. and is marketed in Japan and Korea to treat post-stroke complications and bronchial asthma.